Immunomodulation by treatment with Lactobacillus casei strain Shirota

International Journal of Food Microbiology

Volumn 41, Issue 2, 1998, Pages 133-140

  Matsuzaki, Takeshi ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

Anti tumour activity; Immunomodulation; Lactobacillus casei strain Shirota; Oral administration

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; IMMUNE SYSTEM; IMMUNOMODULATION; LACTOBACILLUS CASEI; MITOGENESIS; MOUSE; NONHUMAN; RAT; REVIEW; STRAIN DIFFERENCE; SURVIVAL TIME; THORAX; TUMOR CELL;

ANIMALIA; LACTOBACILLUS CASEI; POSIBACTERIA; RODENTIA;

EID: 0032568569     PISSN: 01681605     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1605(98)00046-4     Document Type: Article

References (23)

1. Asano, M., 1989. Lactobacillus casei, immunology and cancer. In: The Story of Lactobacillus casei and Cancer. Bunshodo, Tokyo.
2. Aso, Y., Akaza, H., the BLP Study Group, 1992. Prophylactic effects of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urol. Int. 49, 125-129.
3. Aso, Y., Akaza, H., Kotake, T., Tsukamoto, T., Imai, K., Naito, S., the BLP Study Group, 1995. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur. Urol. 27, 104-109.
4. Bakker W., Nijhuis-Heddes J.M.A., van der Velde E.A. Post-operative intrapleural BCG in lung cancer: A 5-year follow-up report. Cancer Immunol. Immunother. 22:1986;155-159.
5. Kato I., Kobayashi S., Yokokura T., Mutai M. Anti-tumour activity of Lactobacillus casei in mice. Gann. 72:1981;517-523.
6. Kato I., Yokokura T., Mutai M. Augmentation of mouse natural killer cell activity by Lactobacillus casei and its surface antigens. Microbiol. Immunol. 28:1984;209-217.
7. Kato I., Endo K., Yokokura T. Induction of anti-tumour activity with oral administration of Lactobacillus casei in mice. Biotherapy. 6:1992;1121-1126.
8. Kato I., Endo K., Yokokura T. Effects of oral administration of Lactobacillus casei on anti-tumour responses induced by tumour resection in mice. Int. J. Immunopharmacol. 16:1994;29-36.
9. Luh K.T., Yang P.C., Kuo S.H., Chang D.B., Yu C.J., Lee L.N. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. Cancer. 69:1992;674-679.
10. Masuno T., Kishimoto S., Ogura T., Honma T., Niitani H., Fukuoka M., Ogawa N. A comparative trial of LC 9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer. 68:1991;1495-1500.
11. Masuno T., Kishimoto S., Ogura T., Honma T., Niitani H., Fukuoka M., Ogawa N. Control of carcinomatous pleural effusion with LC 9018 and quality of life in lung cancer patients. Biotherapy. 8:1994;847-856.
12. Matsuzaki T., Yokokura T., Azuma I. Anti-tumour activity of Lactobacillus casei on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs. Cancer Immunol. Immunother. 20:1985;18-22.
13. Matsuzaki T., Yokokura T., Azuma I. Anti-metastatic effect of Lactobacillus casei YIT9018 (LC 9018) on a highly metastatic variant of B16 melanoma in C57BL/6J mice. Cancer Immunol. Immunother. 24:1987;99-105.
14. Matsuzaki T., Yokokura T. Inhibition of tumour metastasis of Lewis lung carcinoma in C57BL/6 mice by intrapleural administration of Lactobacillus casei. Cancer Immunol. Immunother. 25:1987;100-104.
15. Matsuzaki T., Yokokura T., Mutai M. The role of lymph node cells in the inhibition of metastasis by subcutaneous injection of Lactobacillus casei in mice. Med. Microbiol. Immunol. 177:1988;245-253.
16. Matsuzaki T., Yokokura T., Mutai M. Anti-tumour effect of intrapleural administration of Lactobacillus casei. Cancer Immunol. Immunother. 26:1988;209-214.
17. Matsuzaki T., Shimizu Y., Yokokura T. Augmentation of anti-metastatic effect on Lewis lung carcinoma (3LL) in C57BL/6 mice by priming with Lactobacillus casei. Med. Microbiol. Immunol. 179:1990;161-168.
18. Matsuzaki T., Hashimoto S., Yokokura T. Effects on anti-tumour activity and cytokine production in the thoracic cavity by intrapleural administration of Lactobacillus casei in tumour-bearing mice. Med. Microbiol. Immunol. 185:1996;157-161.
19. Sawamura A., Yamaguchi Y., Toge T., Nagata N., Ikeda H., Nakanishi K., Asakura A. The enhancing effect of oral Lactobacillus casei on the immunologic activity of colon cancer patients. Biotherapy. 8:1994;1567-1572.
20. Tomita K., Akaza H., Nomoto K., Yokokura T., Matsushita H., Honma Y., Aso Y. Influence of Lactobacillus casei on rat bladder carcinogenesis. Nihon Hinyoukika Gakkai. 85:1994;655-663.
21. Uchida A., Micksche M. Randomized controlled study of OK-432 in the treatment of cancerous pleurisy. Jpn. J. Cancer Chemother. 10:1983;1497-1503.
22. Yokokura, T., Kato, I., Mutai, M., 1981. Antitumour effect of Lactobacillus casei (LC 9018). In: Mitsuoka, T. (Ed.), Intestinal Flora and Carcinogenesis. Gakkai-Syuppan Center, Tokyo, pp. 72-88.
23. Yokokura, T., 1994. Anti-tumour and immuno-stimulating activities of orally administered Lactobacillus casei. In: The Third International Symposium on Intestinal Flora. Intestinal Flora and Human Health, 72-88.